Sprache auswählen
CD8 alpha
CD8 alpha Molekülinformation
| Englischer Name | Cluster of differentiation 8 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 18 | Target-Alias | CD8 Antigens |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical | ||
| Englischer Name | Cluster of differentiation 8 |
| Target-Alias | CD8 Antigens |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 18 |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical |
CD8 alpha Produktliste
- Attribut
Protein (13)
- Produktbibliothek
Online (13)
- Spezies
Mouse (3)Human (8)Cynomolgus (2)
- Etikett
His Tag & Avi Tag (4)His Tag (8)Fc Tag (1)
- Marker
Biotin-labeled (3)Unconjugated (4)AF488 Labeled (3)AF647 Labeled (1)PE Labeled (1)APC Labeled (1)
In den Warenkorb legen
Gesamtmenge13
- 1
- 2
CD8 alpha Molekülhintergrund
Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells.
CD8 alpha Molekülalias
CD8A,CD8,Leu2,MAL,p32
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| 89Zr-Df-crefmirlimab | IAB-22-M2C | Phase 3 Clinical | Imaginab Inc | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Leukoencephalopathy, Progressive Multifocal; Lymphoma; Melanoma; Multiple Sclerosis; Skin Melanoma; Solid tumours | Details |
| RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | Details |
| CD8+ memory T cell therapy (Stanford University) | Phase 2 Clinical | Stanford University | Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck | Details |
| VE-800 | VE-800 | Phase 2 Clinical | Vedanta Biosciences Inc | Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Neoplasm Metastasis; Stomach Neoplasms | Details |
| EBViNT Cell (Eutilex) | Phase 2 Clinical | Eutilex | Lymphoma, Extranodal NK-T-Cell | Details | |
| ZED88082A | ZED88082A | Phase 2 Clinical | Umcg The University Medical Center Groningen | Neoplasm Metastasis; Neoplasms | Details |
| AZD-6750 | AZD6750; AZD-6750 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Melanoma; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| AZD-9793 | AZD9793; AZD-9793 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular; Neoplasm Metastasis; Solid tumours | Details |
| AZD-5492 | AZD5492 | Phase 2 Clinical | Astrazeneca Plc | Arthritis, Rheumatoid; Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Myositis; Neoplasms | Details |
| SNA-006 | 68-Ga-NODAGA-SNA-006; 68Ga-NODAGA-SNA006; SNA-006 | Phase 2 Clinical | Smartnuclide Biopharma | Neoplasms; Solid tumours | Details |
| NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Liposarcoma; Sarcoma; Sarcoma, Synovial | Details | |
| MTX-101 (Mozart Therapeutics) | MTX-101 (Mozart Therapeutics) | Phase 1 Clinical | Mozart Therapeutics Inc | Autoimmune Diseases; Diabetes Mellitus, Type 1 | Details |
| [18F]GEH200521 | GEH200521 (18F); GEH-200521 | Phase 1 Clinical | Ge Healthcare | Solid tumours | Details |
| Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Gastroesophageal Junction Neoplasms; Stomach Neoplasms | Details | |
| SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
| 89Zr-DFO-REGN5054 | 89Zr-DFO-REGN5054 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours | Details |
| AGX-148 | AGX-148; AGX148 | Phase 1 Clinical | AgonOx Inc | Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urogenital Neoplasms | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main